Literature DB >> 10934251

Neuropathology in mice expressing human alpha-synuclein.

H van der Putten1, K H Wiederhold, A Probst, S Barbieri, C Mistl, S Danner, S Kauffmann, K Hofele, W P Spooren, M A Ruegg, S Lin, P Caroni, B Sommer, M Tolnay, G Bilbe.   

Abstract

The presynaptic protein alpha-synuclein is a prime suspect for contributing to Lewy pathology and clinical aspects of diseases, including Parkinson's disease, dementia with Lewy bodies, and a Lewy body variant of Alzheimer's disease. alpha-Synuclein accumulates in Lewy bodies and Lewy neurites, and two missense mutations (A53T and A30P) in the alpha-synuclein gene are genetically linked to rare familial forms of Parkinson's disease. Under control of mouse Thy1 regulatory sequences, expression of A53T mutant human alpha-synuclein in the nervous system of transgenic mice generated animals with neuronal alpha-synucleinopathy, features strikingly similar to those observed in human brains with Lewy pathology, neuronal degeneration, and motor defects, despite a lack of transgene expression in dopaminergic neurons of the substantia nigra pars compacta. Neurons in brainstem and motor neurons appeared particularly vulnerable. Motor neuron pathology included axonal damage and denervation of neuromuscular junctions in several muscles examined, suggesting that alpha-synuclein interfered with a universal mechanism of synapse maintenance. Thy1 transgene expression of wild-type human alpha-synuclein resulted in similar pathological changes, thus supporting a central role for mutant and wild-type alpha-synuclein in familial and idiotypic forms of diseases with neuronal alpha-synucleinopathy and Lewy pathology. These mouse models provide a means to address fundamental aspects of alpha-synucleinopathy and test therapeutic strategies.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10934251      PMCID: PMC6772584     

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  54 in total

1.  MPTP induces alpha-synuclein aggregation in the substantia nigra of baboons.

Authors:  N W Kowall; P Hantraye; E Brouillet; M F Beal; A C McKee; R J Ferrante
Journal:  Neuroreport       Date:  2000-01-17       Impact factor: 1.837

2.  The ubiquitin pathway in Parkinson's disease.

Authors:  E Leroy; R Boyer; G Auburger; B Leube; G Ulm; E Mezey; G Harta; M J Brownstein; S Jonnalagada; T Chernova; A Dehejia; C Lavedan; T Gasser; P J Steinbach; K D Wilkinson; M H Polymeropoulos
Journal:  Nature       Date:  1998-10-01       Impact factor: 49.962

3.  Alpha synuclein is present in Lewy bodies in sporadic Parkinson's disease.

Authors:  E Mezey; A M Dehejia; G Harta; N Tresser; S F Suchy; R L Nussbaum; M J Brownstein; M H Polymeropoulos
Journal:  Mol Psychiatry       Date:  1998-11       Impact factor: 15.992

4.  Failure to find the alpha-synuclein gene missense mutation (G209A) in 100 patients with younger onset Parkinson's disease.

Authors:  P Chan; C M Tanner; X Jiang; J W Langston
Journal:  Neurology       Date:  1998-02       Impact factor: 9.910

5.  Mutation in the alpha-synuclein gene identified in families with Parkinson's disease.

Authors:  M H Polymeropoulos; C Lavedan; E Leroy; S E Ide; A Dehejia; A Dutra; B Pike; H Root; J Rubenstein; R Boyer; E S Stenroos; S Chandrasekharappa; A Athanassiadou; T Papapetropoulos; W G Johnson; A M Lazzarini; R C Duvoisin; G Di Iorio; L I Golbe; R L Nussbaum
Journal:  Science       Date:  1997-06-27       Impact factor: 47.728

6.  Endogenous serine protease inhibitor modulates epileptic activity and hippocampal long-term potentiation.

Authors:  A Lüthi; H Van der Putten; F M Botteri; I M Mansuy; M Meins; U Frey; G Sansig; C Portet; M Schmutz; M Schröder; C Nitsch; J P Laurent; D Monard
Journal:  J Neurosci       Date:  1997-06-15       Impact factor: 6.167

7.  NACP, a presynaptic protein, immunoreactivity in Lewy bodies in Parkinson's disease.

Authors:  K Wakabayashi; K Matsumoto; K Takayama; M Yoshimoto; H Takahashi
Journal:  Neurosci Lett       Date:  1997-12-12       Impact factor: 3.046

8.  Ubiquitin carboxyl-terminal hydrolase (PGP 9.5) is selectively present in ubiquitinated inclusion bodies characteristic of human neurodegenerative diseases.

Authors:  J Lowe; H McDermott; M Landon; R J Mayer; K D Wilkinson
Journal:  J Pathol       Date:  1990-06       Impact factor: 7.996

9.  alpha-Synuclein gene and Parkinson's disease. The French Parkinson's Disease Study Group.

Authors: 
Journal:  Science       Date:  1998-02-20       Impact factor: 47.728

10.  Argyrophilic glial inclusions in the midbrain of patients with Parkinson's disease and diffuse Lewy body disease are immunopositive for NACP/alpha-synuclein.

Authors:  T Arai; K Uéda; K Ikeda; H Akiyama; C Haga; H Kondo; N Kuroki; K Niizato; S Iritani; K Tsuchiya
Journal:  Neurosci Lett       Date:  1999-01-08       Impact factor: 3.046

View more
  143 in total

1.  Selective insolubility of alpha-synuclein in human Lewy body diseases is recapitulated in a transgenic mouse model.

Authors:  P J Kahle; M Neumann; L Ozmen; V Müller; S Odoy; N Okamoto; H Jacobsen; T Iwatsubo; J Q Trojanowski; H Takahashi; K Wakabayashi; N Bogdanovic; P Riederer; H A Kretzschmar; C Haass
Journal:  Am J Pathol       Date:  2001-12       Impact factor: 4.307

Review 2.  Lewy bodies and dementia.

Authors:  D Galasko
Journal:  Curr Neurol Neurosci Rep       Date:  2001-09       Impact factor: 5.081

Review 3.  Modeling human neurodegenerative diseases in transgenic systems.

Authors:  Miguel A Gama Sosa; Rita De Gasperi; Gregory A Elder
Journal:  Hum Genet       Date:  2011-12-14       Impact factor: 4.132

Review 4.  Parkinson's disease: a rethink of rodent models.

Authors:  Heather L Melrose; Sarah J Lincoln; Glenn M Tyndall; Matthew J Farrer
Journal:  Exp Brain Res       Date:  2006-04-26       Impact factor: 1.972

Review 5.  Etiology of Parkinson's disease: Genetics and environment revisited.

Authors:  Kathy Steece-Collier; Eleonora Maries; Jeffrey H Kordower
Journal:  Proc Natl Acad Sci U S A       Date:  2002-10-21       Impact factor: 11.205

Review 6.  Rare genetic mutations shed light on the pathogenesis of Parkinson disease.

Authors:  Ted M Dawson; Valina L Dawson
Journal:  J Clin Invest       Date:  2003-01       Impact factor: 14.808

7.  Increased dopaminergic neuron sensitivity to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in transgenic mice expressing mutant A53T alpha-synuclein.

Authors:  Wai Haung Yu; Yasuji Matsuoka; István Sziráki; Audrey Hashim; John Lafrancois; Henry Sershen; Karen E Duff
Journal:  Neurochem Res       Date:  2007-11-13       Impact factor: 3.996

8.  Mitochondrial permeability transition pore regulates Parkinson's disease development in mutant α-synuclein transgenic mice.

Authors:  Lee J Martin; Samantha Semenkow; Allison Hanaford; Margaret Wong
Journal:  Neurobiol Aging       Date:  2013-11-16       Impact factor: 4.673

9.  Alpha-synuclein targets the plasma membrane via the secretory pathway and induces toxicity in yeast.

Authors:  Cheryl Dixon; Neal Mathias; Richard M Zweig; Donnie A Davis; David S Gross
Journal:  Genetics       Date:  2005-03-02       Impact factor: 4.562

10.  Next-generation active immunization approach for synucleinopathies: implications for Parkinson's disease clinical trials.

Authors:  Markus Mandler; Elvira Valera; Edward Rockenstein; Harald Weninger; Christina Patrick; Anthony Adame; Radmila Santic; Stefanie Meindl; Benjamin Vigl; Oskar Smrzka; Achim Schneeberger; Frank Mattner; Eliezer Masliah
Journal:  Acta Neuropathol       Date:  2014-02-14       Impact factor: 17.088

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.